Daraxonrasib Breakthrough: New Oral Treatment Significantly Improves Pancreatic Cancer Survival Rates
A New Frontier in Oncology In a landmark Phase 3 clinical trial, the experimental drug Daraxonrasib has demonstrated a 60% reduction in the risk of death for patients suffering from advanced pancreatic cancer. The results, unveiled this week by the Clinical Trial Vanguard, indicate that the daily oral medication effectively doubles the median survival time…